Cystic Fibrosis Trial, Recruiting NCT05937815 Sponsor: University Hospital, Bordeaux Condition: Cystic Fibrosis
Back to Cystic Fibrosis

Cystic Fibrosis Trial, Recruiting

NCT05937815
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have cystic fibrosis, confirmed by a sweat test result above 60 mmol/l
  • People who carry at least one copy of the DeltaF508 gene mutation associated with cystic fibrosis
  • People whose ongoing care is provided by a cystic fibrosis centre that is part of this study
  • People for whom a treating doctor is starting the combination treatment elexacaftor/tezacaftor/ivacaftor as part of their regular care, in line with the approved uses of this medication at the time of joining
  • People who fall within the age range specified by the current approved guidelines for this medication
  • People who are covered by the French social security system
  • People (or, for children, their parents or legal guardians) who have given their consent to take part before any study-related assessments are carried out
  • People who agree to be included in follow-up studies for patients treated with elexacaftor/tezacaftor/ivacaftor, as part of the French cystic fibrosis patient registry

Who may not be able to join:

  • People who are starting elexacaftor/tezacaftor/ivacaftor as part of another clinical trial, rather than as part of their routine care
  • People who are already taking a CFTR modulator medication, including the combination lumacaftor/ivacaftor
  • People who are pregnant, or who are under legal guardianship or curatorship

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Raphaël Enaud, MDPhD, University Hospital, Bordeaux

Phone: 0557820877

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
13 September 2021
Est. completion
13 September 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

composition of the digestive bacterial microbiota

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov